Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-276,400
Closed -$2.22M 1565
2024
Q4
$2.22M Sell
276,400
-373,200
-57% -$3.6M 0.02% 572
2024
Q3
$8.2M Sell
649,600
-380,100
-37% -$4.91M 0.07% 251
2024
Q2
$13M Buy
1,029,700
+460,400
+81% +$4.63M 0.11% 165
2024
Q1
$2.72M Sell
569,300
-902,300
-61% -$4.18M 0.03% 476
2023
Q4
$7.06M Sell
1,471,600
-507,800
-26% -$3.11M 0.08% 246
2023
Q3
$14.3M Buy
1,979,400
+375,600
+23% +$3M 0.16% 144
2023
Q2
$11.9M Buy
+1,603,800
New +$12.6M 0.13% 171
2022
Q4
Sell
-396,100
Closed -$7.21M 1220
2022
Q3
$7.21M Buy
+396,100
New +$17.2M 0.13% 200
2022
Q1
Sell
-1,534,700
Closed -$220M 1320
2021
Q4
$220M Buy
+1,534,700
New +$264M 2.24% 4

Other funds holding NVAX

LMR Partners's NVAX Position: Q1 2025 in Review

LMR Partners sold out of Novavax (NVAX) in Q1 2025, closing a stake of 31,613 shares — an estimated $254K sold.

LMR Partners first reported a position in NVAX in Q4 2020 and held it in 8 quarters. The position peaked at $33.2M in Q4 2021. 245 funds tracked by Wall St. Rank hold NVAX as of Q1 2025.

  • LMR Partners reported no remaining Novavax position as of Q1 2025 after selling out during the quarter.
  • LMR Partners sold 31,613 Novavax shares in Q1 2025, an estimated $254K.
  • LMR Partners first reported a position in Novavax in Q4 2020 and held it in 8 quarters.
  • LMR Partners's Novavax position peaked at $33.2M in Q4 2021.
  • 245 funds tracked by Wall St. Rank held Novavax as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.